TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., July 18, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on July 15, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,522 shares of its common stock and an aggregate of 6,240 restricted stock units to 5 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
2024年7月18日麻省安多弗/美通社——TransMedics公司（“TransMedics”）（納斯達克：TMDX）是一家醫療技術公司，正在爲患有末期肺部、心臟和肝功能衰竭的患者轉化器官移植治療，今日宣佈，於2024年7月15日，TransMedics授予5名員工非符合條件的股票期權，以購買其普通股股票合計9522股以及6240個限制性股票單位，作爲每位員工進入TransMedics公司的物質誘因。這些授予獲得了TransMedics董事會薪酬委員會的批准，並根據納斯達克列表規則5635（c）（4）和TransMedics Group, Inc.誘因計劃授權。
TransMedics granted non-qualified stock options to purchase 9,522 shares of TransMedics' common stock and 6,240 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $144.35, the closing price of the common stock on the Nasdaq Global Market on July 15, 2024. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.
TransMedics授予非符合條件的股票期權，購買TransMedics普通股合計9522股和6240個限制性股票單位。這些股票期權的行權價格爲144.35美元/股，即2024年7月15日納斯達克全球市場的收盤價。每個期權股票的股票數量的25%將於員工就職一週年的紀念日解除限制，其餘股票將均勻地在接下來的三年內每月解除限制，前提是員工在適用的解除限制日期之前繼續爲公司服務。這些期權有10年期限，適用TransMedics Group, Inc.誘因計劃條款。每個限制性股票單元獎勵的25%將於員工就職四週年的紀念日解除限制，前提是員工在適用的解除限制日期之前繼續爲公司服務。這些限制性股票單元適用TransMedics Group, Inc.誘因計劃條款。
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
關於transmedics公司
transmedics是世界上便攜式體外溫熱灌注和評估供體器官移植的領先者。該公司總部位於美國馬薩諸塞州安多弗，旨在解決器官移植的需求問題，開發出了保存器官質量、評估器官移植前的可能性和潛在增加供體器官利用率的技術，用於治療終末心臟、肺和肝功能衰竭。
Investor Contact:
Brian Johnston
332-895-3222
[email protected]
投資者聯繫：
Brian Johnston
332-895-3222
[email protected]
SOURCE TransMedics Group, Inc.
資料來源：transmedics group，inc。